not. It could simply be that a healthier subset is interested in the prevention logic of the HMOs. If there is any problem, it is with the reimbursement logic, not with the provider. Similarly, there is no implication that the PACE sites may have been disingenuous either.
What the preliminary data do suggest, however, is that a fuller discussion of the basis for PACE capitation payments in particular, and PACE reimbursements in general, are in order. To that end, I had prepared another manuscript, one that argues that the current HCFA financial reporting requirements make it virtually impossible to know how much the PACE programs cost in terms of public and private monies. Unfortunately, HCFA has not released that manuscript for peer review in order to enlighten this important discussion.
In summary, our original article did not conclude that niche marketing/skimming was in fact occurring, but raised the possibility. But this concept is a proverbial hot button in our field because of its implications. Clearly, HCFA does not want anyone suggesting that they are overpaying, and the sites do not want anyone saying that could reduce their capitation payments. But these are public monies and public discussion is warranted. I urge Dr. Vladeck to override his staff and release the subsequent manuscript. In his article, "The Alzheimerization of Aging," Richard C. Adelman commented that the National Institute on Aging (NIA) invests a disproportionately large share of its resources in research on Alzheimer's disease at the expense of other interests of the broader scientific community in gerontology. He believes that the support of Alzheimer's disease is so large that only trivial amounts of support are available for other areas of interest in gerontology.
Readers of The Cerontologist need to take into account several key issues in reflecting upon Dr. Adelman's commentary. We agree that funding for fundamental gerontology research is unfortunately low and support advocacy by the gerontology community. We strongly disagree, however, that current fundingforAlzheimer's disease is disproportionately large or that it can be blamed for inadequate funding of other areas of research. The explosive growth of neuroscience research and of research on Alzheimer's disease in particular is not the result of marketing or the actions of a cabal, and it is not even dependent upon the label of Alzheimer's disease. Instead, increased funding reflects significant improvements in scientific technique and knowledge that provide hope of major scientific advances. It also reflects a definite and critical need perceived by the public and acted upon by Congress. The importance of dementia is not a narrow interest of investigators or physicians, but is widely recognized in the aging community, as evidenced by placement of Alzheimer's research as the second item recommended in preparation for the White House Conference on Aging (Tangalos & Katz, 1995) .
The amount of funding for Alzheimer's disease needs to be compared to the cost to our society of this dreadful disease. Recent estimates place the cost of Alzheimer's disease in the United States at more than $80 billion per year (U.S. Congress, Office of Technology Assessment, 1987) . By comparison, the allocation that the NIA provides for basic and clinical research on Alzheimer's disease seems paltry. At least 80% of NIA funds devoted to Alzheimer's disease support basic research. The investigations involve basic biological sciences, including molecular biology, structural biology and genetics. Several extraordinarily important discoveries that have been made recently demonstrate that research support for Alzheimer's disease is cost-effective. These discoveries include the cloning of genes on chromosomes 1 and 14 (Levy-Lahad et al., 1995; Sherrington et al., 1995) responsible for two early onset familial types of Alzheimer's disease, recognition of the key role of apolipoprotein E4 and brain reserve as risk factors in late-onset Alzheimer's disease, delineation of the natural history of mild memory impairment (Katzman, 1993; Katzman et al., 1988; Zhang et al., 1990) , and the clinical features of related conditions. Funds allocated by the NIA for Alzheimer's Disease Centers were newly appropriated; they had not been invested elsewhere, and if they had not been allocated to research in Alzheimer's disease, it is likely that they would not have been assigned to the National Institutes of Health at all. There is no evidence that these funds were removed from other areas of investigation in gerontology and applied to research on Alzheimer's disease. Readers of Dr. Adelman's commentary should keep in mind that research on many of the diseases affecting the elderly such as cancer, arthritis, osteoporosis and heart disease are already supported by other institutes in the National Institutes of Health. Alzheimer's disease is the only serious disorder of aging that was not of particular interest to a major institute until the NIA developed its Alzheimer's disease research program. Limiting the focus of discussion to the NIA gives the impression that the funding for research in Alzheimer's disease is excessive, but this is patently untrue. For example, the National Cancer Institute allocates approximately $1 billion per year to investigate the causes and treatments of cancer. Small budgets for both Alzheimer's disease and gerontology research reflect in part the only recent recognition of the importance of these areas of inquiry. Unfortunately,
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in these periods when it is difficult to find funding for new initiatives, our best hope may be to maintain current levels of funding. Extending cultural wars in gerontology to the political arena is unnecessary and will only diminish the combatants. Webster's Dictionary defines the term "cabal" as "a small group of persons joined in a secret, often political intrigue" (Guralnik, 1974) . The likelihood of significant contributions by any such entity to the current status of NIA support for Alzheimer's disease-related research is a fascinating, although perhaps excessive speculation that the Gilman/ Foster letter contains, whereas my article does not. The significance of science-driven intellectual growth to this area of research is both self-evident and also within the abstract of my letter.
At the same time, to profess that social forces do not shape science is a naive denial of recent history (e.g., Zuckerman, 1988 ) and a still-growing body of research.
The issue of budgetary balance within the Federal support of science is extraordinarily complex. For example, to what relative extent is Gilman's and Foster's example of the billion dollar budget of the National Cancer Institute a consequence of scientific accomplishment and/or the use/abuse of knowledge by interest groups (e.g., Proctor, 1995) ? Furthermore, what will it take to make the U.S. Congress and the general public understand that the most important medical discoveries are most often the serendipitous result of curiosity-driven science, rather than Federal declarations of war against disease?
The scope of public perception of the relative importance of Alzheimer's disease awaits completion of ongoing research, notwithstanding one stipulated priority of the recent White House Conference on Aging.
Finally, I am most saddened by Gilman's and Foster's concluding sentence:
"Extending cultural wars in gerontology to the political arena is unnecessary and will only diminish the combatants."
The traditional exponential growth rate of science is diminishing (De Solla Price, 1986) as society challenges science's values, credibility and fiscal base (e.g., . At least in my opinion, society has the right to do so in the context of equally important alternative needs. However, within the context of available funding, it is the active scientists whose priorities are most important. Thus, this type of interchange does not demean us; it is as critical as our data to the survival of meritorious science. That is precisely why the primary intent of my article is to provoke the basic science community and its advocates (e.g., GSA) in gerontology to develop the sophisticated social presence that already characterizes the Alzheimer's movement and others. 
